Chris Schott

Why This Gilead Analyst Believes The Stock Is Highly Undervalued

What Drove Merck's Keytruda Shortfall In Q4

Teva Vs. Amneal: JPMorgan Sees Hope For One, Decline For The Other

What Drove Merck's Keytruda Shortfall In Q4

Teva Vs. Amneal: JPMorgan Sees Hope For One, Decline For The Other

Eli Lilly Could Sustain Industry-Leading Growth, Says Bullish JPMorgan

For Teva Pharmaceuticals, No Recovery In Sight, Says Analyst

Eli Lilly Could Sustain Industry-Leading Growth, Says Bullish JPMorgan

For Teva Pharmaceuticals, No Recovery In Sight, Says Analyst

Do Valeant Fundamentals Justify The Decrease In Bearish Sentiment?

Here's What The FDA Approval Of Keytruda Means For Merck, And For Bristol-Myers

Chris Schott Recent News

Recent Deals, Pipeline Updates Setting Up AbbVie For Long-Term Growth

New Upside Potential Drives JPMorgan's Eli Lilly Upgrade

Valeant Gets First Downgrade In Over 3 Months

JPMorgan's Take On Big Pharma's New ASCO Abstracts

JPMorgan On Allergan: Solid Core Product Performance

Pfizer's Valuation Is Attractive, And JPMorgan Wouldn't Be Surprised To See A Breakup

JPMorgan Isn't Concerned About Valeant's Ad Hoc Committee At All; Says Sum-Of-The-Parts Shows Upside

Some On Wall Street Still Back Valeant

Valeant Has More Volatility Coming, JPMorgan Says

Pfizer, Allergan In 'Final Innings' Of Merger Talks

Time To Buy Mylan's Clear Path To EPS Upside, JP Morgan Says

How Allergan Could Be Pfizer's Rocket Ship

Wall Street Defends AbbVie, Says Reaction Is Overdone

Calls Of Note: The Street's Research Moving Stocks This Monday

Analyst Finds Perrigo 'Still Attractive' As Take Out Target

JPMorgan Says Mylan Has 3 Paths To Upside

Will Actavis Win Competition For Allergan's Affection?

Pfizer Inc. Is Kicking The Tires At Actavis PLC

UPDATE: JP Morgan Upgrades Teva Pharmaceuticals

UPDATE: J.P. Morgan Downgrades Teva Pharmaceutical on Too Much Uncertainty Following CEO Departure

UPDATE: J.P. Morgan Upgrades Bristol-Myers Squibb Ahead of Multiple Important Catalysts

UPDATE: J.P. Morgan Downgrades Teva, Says No Near-Term Upside in Sight

J.P. Morgan Reiterates Overweight Rating on Zoetis Following Prizer Share Exchange